Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
VIR filed a Form 144 notice to sell 88,000 pre-IPO common shares. The filing lists the securities to be sold as 88,000 Pre-IPO Shares with an original date of 01/17/2017. The excerpt also shows prior 10b5-1 sales by Vicki Lee Sato: 22,000 shares on 01/02/2026, 22,000 shares on 02/02/2026, and 42,377 shares on 02/24/2026.
Vir Biotechnology, Inc. completed a public offering of common stock to raise new capital. The company sold 17,647,059 shares at $8.50 per share under an underwriting agreement with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C., and Barclays Capital Inc.
The underwriters fully exercised a 30-day option to buy an additional 2,647,058 shares. As a result, Vir Biotechnology issued a total of 20,294,117 shares of common stock, generating aggregate gross proceeds of approximately $172.5 million before underwriting discounts, commissions, and offering expenses.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at $8.50 per share under an underwriting agreement with Goldman Sachs, Leerink Partners, Evercore and Barclays. The offering is expected to close on February 27, 2026, subject to customary conditions.
The underwriters have a 30-day option to buy up to an additional 2,647,058 shares at the public offering price. Vir Biotechnology expects net proceeds of approximately $141.1 million, or about $162.3 million if the option is fully exercised, after underwriting discounts, commissions and estimated expenses.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at a public offering price of $8.50 per share, with an underwriter option to purchase up to 2,647,058 additional shares for 30 days.
The offering is expected to provide net proceeds of approximately $141.1 million (or $162.3 million if the underwriters exercise their option in full), which Vir says it will use to fund its share of global clinical development and potential commercial launch costs for VIR-5500, other TCE programs using the PRO-XTEN® platform, and for working capital and general corporate purposes.
Vir Biotechnology director Vicki L. Sato reported option exercises and related share sales. She exercised a stock option for 42,377 shares of common stock at a price of $1.485 per share and received common shares upon exercise.
On the same date, she sold 42,377 common shares in open-market transactions, including 42,177 shares at a weighted average price of $9.7521 per share and 200 shares at $10.26 per share. The weighted-average sale involved multiple trades between $9.23 and $10.20 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025. After these transactions, she directly owned 1,144,391 Vir Biotechnology common shares.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an automatic sale of 1,430 shares of common stock. The shares were sold at an average price of $9.5326 per share under a Rule 10b5-1 plan to cover tax withholding on vested restricted stock units. After this non-discretionary transaction, he directly holds 69,613 shares.
Vir Biotechnology EVP & CFO Jason O'Byrne reported an automatic sale of 1,634 shares of common stock in an open-market transaction on February 24, 2026 at an average price of $9.5326 per share. According to the disclosure, this was a mandatory sale under a Rule 10b5-1 plan to cover the company’s tax withholding obligations tied to the vesting of restricted stock units, and not a discretionary trade by O'Byrne. After this tax-related sale, he beneficially owned 162,615 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive vice president and chief medical officer Mark Eisner reported two open-market sales of common stock under a pre-set Rule 10b5-1 trading plan. On February 24, 2026, he sold 1,616 shares at an average price of $9.5326 per share. On February 25, 2026, he sold another 1,889 shares at an average price of $9.82 per share. A footnote states the February 25 sale was an automatic, mandatory sale to cover tax withholding from vested restricted stock units rather than a discretionary trade. After these transactions, Eisner directly owned 154,024 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive Vanina de Verneuil, EVP, General Counsel and Corporate Secretary, reported two open-market sales of common stock. She sold 13,700 shares on February 25, 2026 at $9.82 per share and 3,117 shares on February 24, 2026 at $9.5326 per share.
The 13,700-share sale was an automatic, mandatory transaction under Rule 10b5-1 to cover tax withholding on vesting restricted stock units and was not a discretionary trade. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2025, and she held 112,982 shares directly after the last reported sale.
Vir Biotechnology, Inc. Chief Executive Officer Marianne De Backer reported an automatic sale of common stock tied to tax withholding. On this transaction date, 14,762 shares of common stock were sold in an open-market transaction at an average price of $9.5326 per share under a Rule 10b5-1 arrangement to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and the filing states the sale was not a discretionary trade by her. After this sale, she held 1,020,704 shares of Vir Biotechnology common stock directly and 53,118 shares indirectly through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.